Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)
August 4, 2025 2:10 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).
The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More
Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush
August 4, 2025 1:24 PM EDTWedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.
The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More
Praxis Precision Medicines (PRAX) Misses Q2 EPS by 6c
August 4, 2025 9:05 AM EDTPraxis Precision Medicines (NASDAQ: PRAX) reported Q2 EPS of ($3.31), $0.06 worse than the analyst estimate of ($3.25).
For earnings history and earnings-related data on Praxis Precision Medicines (PRAX) click here.
... MorePraxis reports positive seizure reduction results from vormatrigine trial
August 4, 2025 8:10 AM EDTPraxis Precision Medicines Inc. (NASDAQ: PRAX) announced results from its Phase 2 RADIANT study of vormatrigine in patients with focal onset seizures. The 8-week study showed a 56.3% median reduction in seizure frequency, according to the company's statement.
Approximately 22% of patients achieved complete seizure elimination during the final 28 days of treatment. More than 54% of patients... More
